{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2(2)"],"submitter":["Vasku V"],"pubmed_abstract":["Leptin has recently attracted more attention due to its specific effects in the pathogenesis of malignancies. The aim of this study was to investigate the possible association between variants of -2548 G/A polymorphism in leptin (LEP) gene and cutaneous T-cell lymphomas (CTCL), with respect to the treatment responsiveness. A sample of 91 patients with CTCL was compared to 198 control individuals. The CTCL men with AG and/or GG genotype were more likely to receive the topical steroids treatment (odds ratio 7.88, 95% confidential interval 1.51-41.04) when compared to AA patients. Our data supports the possible involvement of LEP-2548G/A polymorphism in CTCL treatment responsiveness and thus might provide important information for individual therapy tailoring."],"journal":["International journal of clinical and experimental pathology"],"pagination":["163-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2583633"],"repository":["biostudies-literature"],"pubmed_title":["Pharmacogenetic contribution of leptin gene polymorphism in cutaneous T-cell lymphoma."],"pmcid":["PMC2583633"],"pubmed_authors":["Vasku A","Vasku V","Vasku JB"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacogenetic contribution of leptin gene polymorphism in cutaneous T-cell lymphoma.","description":"Leptin has recently attracted more attention due to its specific effects in the pathogenesis of malignancies. The aim of this study was to investigate the possible association between variants of -2548 G/A polymorphism in leptin (LEP) gene and cutaneous T-cell lymphomas (CTCL), with respect to the treatment responsiveness. A sample of 91 patients with CTCL was compared to 198 control individuals. The CTCL men with AG and/or GG genotype were more likely to receive the topical steroids treatment (odds ratio 7.88, 95% confidential interval 1.51-41.04) when compared to AA patients. Our data supports the possible involvement of LEP-2548G/A polymorphism in CTCL treatment responsiveness and thus might provide important information for individual therapy tailoring.","dates":{"release":"2009-01-01T00:00:00Z","publication":"2009","modification":"2024-10-18T21:08:17.087Z","creation":"2019-03-27T00:19:22Z"},"accession":"S-EPMC2583633","cross_references":{"pubmed":["19079651"]}}